

**IBC Meeting Minutes**

7/10/2025 12:10 PM

CMRI Conference Room 33 &amp; Teams

**MEETING TIME RECORDS****Meeting start time:** 12:12**Meeting end time:** 13:00**VOTING MEMBER ATTENDANCE**

<b>Name of IBC Member</b>	<b>Committee Role</b>	<b>Late Arrival Time</b>	<b>Early Departure Time</b>
Daniel Heruth	Chair, Animal Expert, Lab Rep		
Paul Ramlow	BSO, Animal Expert, Lab Rep		
Tarak Srivastava	Lab Rep		
Vivekanand Yadav (for Todd Bradley)	Alternate Lab Rep		
Tamie Crutchfield	Occupational Health		

**VOTING MEMBERS ABSENT**

Todd Bradley	Co-Chair, Lab Rep		
James Slaughter	Local Non-Affiliated		
Judy Dilts	Local Non-Affiliated		

**NON-VOTING MEMBERS PRESENT**

Foster St. Claire	AV & Ex-Officio		
-------------------	-----------------	--	--

**ADMINISTRATIVE STAFF**

Saskia Miller	Director, ORI		
Lizzie Short	Associate Director, IBC		
Daniel Crabtree	Sr. IBC Manager		
Kelleigh Pearson	Administrative Project Coordinator		

**QUORUM INFORMATION****Number of SAFETY members on the roster:** 7**Number required for quorum:** 4**GUEST NAMES**

No guests at this meeting.

**Conflict of Interest (COI):** Chair reminded the Committee to declare any COI.

**Previous Meeting minutes approved:** Yes

A Member moved to approve, seconded, and motion passed. 5 yes, 2 absent.

## BIOSAFETY COMMITTEE UPDATES

### 1. BSO Updates

None.

### 2. ORI Updates

The Associate Director, IBC stated that per the NIH's implementation update, today's meeting minutes will be posted on the CMRI's new public website for IBC meeting minutes once approved by the committee and appropriate redactions, if any, have been made. This will apply to all meeting minutes going forward.

The Associate Director informed the Committee that her last name has been changed to Short.

The ORI Director stated the Associate Director, IBC will be conducting the NIHs IBC self-assessment this fiscal year. This will help ensure our institution is adhering to best practices as it relates to adhering to NIH policies and regulations. The results of the assessment will be reported to the Committee.

## REVIEW OF SUBMISSIONS

### Amendment

### 3. Review of SAMEND202500020

Title:	Amendment for IBC00089
Investigator:	<a href="#">James O'Brien</a>
Submission ID	SAMEND202500020
Documents Reviewed:	<ul style="list-style-type: none"><li>• cytotune_ips_2_0_sendai_reprog_kit_man.pdf</li><li>• scaRNA list</li><li>• scaRNA expression vector</li><li>• vector components</li><li>• Basic Knockdown Vector Map</li></ul>

**Determination:** Approved

**Last day of continuing review period:** 11/28/2025

### **Comments:**

The Biosafety Officer (BSO) provided an overview of the proposed amendment, explaining that it was brought to a full Committee review due to the inclusion of non-exempt work under the following NIH guidelines:

- **Section III-D:** Experiments Requiring Institutional Biosafety Committee (IBC) Approval Prior to Initiation

- **Section III-D-1:** Experiments Involving Risk Group 2, 3, 4, or Restricted Agents as Host-Vector Systems
- **Section III-D-1-a:** Experiments Introducing Recombinant or Synthetic Nucleic Acid Molecules into Risk Group 2 Agents, typically conducted under Biosafety Level 2 (BL2) containment

The Committee engaged in a discussion regarding the use of induced pluripotent stem cells (iPSCs), with questions on if the research falls under the purview of the IBC or Institutional Human Stem Cell Research Oversight (IHSCRO) Committee. It was noted that a stem cell protocol has been submitted to the IHSCRO Committee for review and approval. The BSO clarified that the research falls under both committees with the IBC focusing on the safety aspects and the IHSCRO Committee focusing specifically on the ethical use of stem cells.

A motion to approve the amendment was made, seconded, and the motion passed.

**Votes:**

**For:** 5  
**Against:** 0  
**Recused:** 0  
**Absent:** 2  
**Abstained:** 0

**Amendment**

**4. Review of SAMEND202500032**

Title:	Amendment for IBC00076
Investigator:	<a href="#">Meghan Freier</a>
Submission ID	SAMEND202500032

**Determination:** Approved

**Last day of continuing review period:** 6/7/2026

**Comments:**

The BSO presented an overview of the amendment, which proposes a change in Principal Investigator (PI) from Dr. Mark Clements to Meghan Freier.

Dr. Clements will be departing from CMH as of July 15, 2025. In the interim, Meghan Freier will assume the role of PI for this protocol. Once a new Medical Director is appointed for the PCRUI, an additional amendment will be submitted to update the PI designation accordingly.

Following further discussion, a motion to approve the amendment was made, seconded, and the motion passed.

**Votes:**

**For:** 5  
**Against:** 0  
**Recused:** 0  
**Absent:** 2  
**Abstained:** 0

**REVIEW OF INCIDENTS**
**5. INC00000004**

Title:	Personnel exposure to Lenti Viral Vectors
Incident ID:	INC00000004
Description:	<p>During the IBC meeting on 5/8/2025, the Committee agreed with the corrective action plan to require additional training for the individual involved in the incident and the laboratory team. Additionally, the IBC, Research Safety, and the Comparative Medicine Center (CMC) will be evaluating the SOPs for sharps and work inside a BSC to identify any potential areas for improvement.</p> <p>Update: The BSO and CMC staff are continuing to assess SOPs. Retraining of the individual and the team has been completed.</p> <p>The NIH Office of Science Policy was notified of the incident on 5/6/2025, on 5/9/2025 they responded stating they have reviewed the information, and no further information is required.</p>
Notes:	<p>The BSO provided an update, noting that the NIH reviewed the proposed corrective action and found it satisfactory. No additional information or follow-up was requested.</p> <p>After further discussion, the Committee concurred that the incident could be closed.</p>

**REVIEW OF OTHER AGENDA ITEMS**
**6. Review of 2024 Annual IBC Member Evaluations Summary:**

Description:	The Associate Director will present an overview of the 2024 Annual IBC Member Evaluations.
Notes:	The Associate Director, IBC discussed the results of the IBC Member Evaluation.

**7. Review of NIH Implementation Update: Dangerous Gain of Function Research:**

Description:	Implementation Update: Terminating or Suspending Dangerous Gain-of-Function Research in Accordance with the Executive Order on Improving the Safety and Security of Biological Research
Notes:	<p>The Associate Director, IBC and the BSO gave an overview of the above.</p> <p>In accordance with the Implementation Update the BSO and IBC Chair conducted a comprehensive review of all ongoing research activities at the CMRI and confirmed that none involve dangerous gain-of-function research. This review was documented in a memo signed by both the IBC Chair and the BSO.</p> <p>Additionally, the CMRI is unlikely to ever conduct research that meets the definition of dangerous gain-of-function. Should research that falls under that category be proposed, it would require explicit approval by the CEO.</p> <p>Following further discussion, the Committee was satisfied with the above resolution.</p>

**ACKNOWLEDGMENTS SECTION**

The following items were approved outside of a convened IBC meeting. The Committee reviewed and acknowledged the following items during this meeting.

ID	Name	State	Specialist	Agenda Type
CR202500008	Continuing Review for IBC00097	Approved	Daniel Crabtree	Admin Approval
SAMEND202500000001	Amendment for IBC00076	Approved	Daniel Crabtree	Admin Approval
SAMEND202500011	New Study Strain	Approved	Elizabeth Short	Admin Approval
SAMEND202500014	Amendment for IBC00057	Approved	Elizabeth Short	Admin Approval
SAMEND202500015	3-25 Amendment for IBC00099	Approved	Daniel Crabtree	Admin Approval
SAMEND202500016	Amendment for IBC00091	Approved	Daniel Crabtree	Admin Approval

ID	Name	State	Specialist	Agenda Type
SAMEND202500021	Amendment for IBC00086	Approved	Daniel Crabtree	Admin Approval
SAMEND202500022	Amendment for IBC00057	Approved	Elizabeth Short	Admin Approval
SAMEND202500023	Addition of personnel	Approved	Daniel Crabtree	Admin Approval
SAMEND202500025	Amendment for IBC00076	Approved	Daniel Crabtree	Admin Approval
SAMEND202500026	Amendment for IBC00077	Approved	Elizabeth Short	Admin Approval
SAMEND202500027	Amendment for IBC00076	Approved	Daniel Crabtree	Admin Approval
SAMEND202500028	Amendment for IBC00080	Approved	Elizabeth Short	Admin Approval
SAMEND202500029	Medical Student Addition/Tech Removal	Approved	Daniel Crabtree	Admin Approval
SAMEND202500030	Amendment for IBC00086	Approved	Daniel Crabtree	Admin Approval
SAMEND202500031	Amendment for IBC00057	Approved	Daniel Crabtree	Admin Approval
SAMENDCR202500000001	Amendment/CR for IBC00095	Approved	Elizabeth Short	Admin Approval
SAMENDCR202500000005	Amendment/CR for IBC00076	Approved	Daniel Crabtree	Admin Approval
SAMENDCR202500000006	Amendment/CR for IBC00075	Approved	Daniel Crabtree	Admin Approval
SAMENDCR202500000007	Amendment/CR for IBC00074	Approved	Daniel Crabtree	Admin Approval
SAMENDCR2025000004	Amendment/CR for IBC00082	Approved	Elizabeth Short	Admin Approval
INC000000004	Personnel exposure to Complete		Daniel Crabtree	Safety Incident

ID	Name	State	Specialist	Agenda Type
	Lenti Viral Vectors			Complete